journal article·2025-06Open access

Crystal structure of etrasimod, C 26 H 26 F 3 NO 3

James A. Kaduk, Anja Dosen, Thomas N. Blanton

Powder Diffraction· Volume 40· Issue 2

Abstract

Abstract The crystal structure of etrasimod has been solved and refined using synchrotron X-ray powder diffraction data and optimized using density functional theory techniques. Etrasimod crystallizes in space group P1 (#1) with a = 10.6131(5), b = 10.7003(5), c = 11.1219(8) Å, α = 72.756(2), β = 76.947(2), γ = 77.340(1)°, V = 1159.28(6) Å 3 , and Z = 2 at 298 K. The crystal structure contains O▬H⋯O hydrogen-bonded etrasimod dimers, which lie in layers approximately parallel to the (2,0,−1) plane. The amino group of each molecule forms an intramolecular N▬H⋯O hydrogen bond to the carbonyl group of the adjacent carboxylic acid group. The powder pattern has been submitted to ICDD for inclusion in the Powder Diffraction File™ (PDF®).
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Crystal structures of chemical compounds · Synthesis and biological activity · Crystallography and molecular interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (36)

Show source-provided references
1. Bravais · 1866
2. 10.1093/nar/gkac95610.1093/nar/gkac956 ↗
3. The Lower Energy Diffraction and Scattering Side-Bounce Beamline for Materials Science at the Canadian Light Source
4. 10.1002/jcc.2315310.1002/jcc.23153 ↗
5. 10.1021/ci049780b10.1021/ci049780b ↗
6. 10.1107/S010876810000723010.1107/S0108768100007230 ↗
7. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
8. 2024
9. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
10. Putz · 2023
11. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
12. 10.1017/S088571562400015010.1017/S0885715624000150 ↗
13. 2013
14. 10.1107/S002188989800600110.1107/S0021889898006001 ↗
15. 10.1107/S090744490804362X10.1107/S090744490804362X ↗
16. 10.1002/anie.19951555110.1002/anie.199515551 ↗
17. 10.3406/bulmi.1907.282010.3406/bulmi.1907.2820 ↗
18. Jones, R. M. , Buzzard, D. J. , Han, S. , Kim, S. H. , Lehmann, J. , Ullman, B. , Moody, J. V. , Zhu, X. , and Stirn, S. . 2013. “Substituted 1,2,3,4-Tetrahydrocyclopenta[B]indol-3-yl)Acetic Acid Derivatives Useful in the Treatment of Autoimmune and Inflammatory Disorders.” United States Patent 8580841B2.
19. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
20. 2023
21. Blackburn, A. C. , Castro, R. O. , Hadd, M. A. , Ma, Y.-A. , Montalban, A. G. , Rueter, J. K. , Selvey, L. A. , Shakya, S. R. , and Carlos, M. . 2019. “Crystalline L-Arginine Salt of (R)-2-(7-(4-Cyclopentyl-3-(Trifluoromethyl)Benzyloxy)-1,2,3,4-Tetrahydrocyclo-Penta[b]indol-3-yl)Acetic Acid (Compound 1) for Use in SIPI Receptor-Associated Disorders.” United State Patent 10301262 B2.
22. 10.1107/S160057672100291010.1107/S1600576721002910 ↗
23. 2024
24. 10.1063/1.46788210.1063/1.467882 ↗
25. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
26. A New Law of Crystal Morphology Extending the Law of Bravais
27. 10.1021/ar00172a00510.1021/ar00172a005 ↗
28. 2023
29. 10.1007/BF0054909610.1007/BF00549096 ↗
30. 10.1107/S205698901901624410.1107/S2056989019016244 ↗
31. 10.1021/acs.jctc.2c0095810.1021/acs.jctc.2c00958 ↗
32. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
33. 10.1107/S205252061800233010.1107/S2052520618002330 ↗
34. 10.1016/0927-0256(96)00008-010.1016/0927-0256(96)00008-0 ↗
35. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
36. 10.1017/S088571561800082910.1017/S0885715618000829 ↗